• Target：
• HER2

• Fields：
• >>EGFR tyrosine kinase inhibitor resistance;>>Endocrine resistance;>>Platinum drug resistance;>>MAPK signaling pathway;>>ErbB signaling pathway;>>Calcium signaling pathway;>>HIF-1 signaling pathway;>>PI3K-Akt signaling pathway;>>Focal adhesion;>>Adherens junction;>>Tight junction;>>Pathways in cancer;>>Proteoglycans in cancer;>>MicroRNAs in cancer;>>Pancreatic cancer;>>Endometrial cancer;>>Prostate cancer;>>Bladder cancer;>>Non-small cell lung cancer;>>Breast cancer;>>Gastric cancer;>>Central carbon metabolism in cancer

• Gene Name：
• ERBB2

• Protein Name：
• Her-2

• Human Gene Id：
• 2064

• Human Swiss Prot No：
• P04626

• Immunogen：
• Synthesized peptide derived from human Her-2 AA range:300-400

• Specificity：
• This antibody detects endogenous levels of HER2

• Formulation：
• PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

• Source：
• Monoclonal, Rabbit IgG1, Kappa

• Dilution：
• IHC 1:100-500, WB 1:500-1000, ELISA 1:5000-20000

• Purification：
• Recombinant Expression and Affinity purified

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog;C erb B2/neu protein;CD340;CD340 antigen;Cerb B2/neu protein;CerbB2;Erb b2 receptor tyrosine kinase 2;ErbB-2 proto-oncogene;ERBB2;ERBB2_HUMAN;HER 2;HER 2/NEU;HER2;Herstatin;Human epidermal growth factor receptor 2;Metastatic lymph node gene 19 protein;MLN 19;MLN19;NEU;NEU proto oncogene;Neuro/glioblastoma derived oncogene homolog;Neuroblastoma/glioblastoma derived oncogene homolog;NGL;p185erbB2;Proto-oncogene c-ErbB-2;Proto-oncogene Neu;Receptor tyrosine-protein kinase erbB-2;TKR1;Tyrosine kinase type cell surface receptor HER2;Tyrosine kinase-type cell surface receptor HER2;V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog);V erb b2 avian erythroblastic leukemia viral oncogene homolog 2;V erb b2 avian erythroblastic leukemia viral oncoprotein 2;V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma deriv

• Molecular Weight(Da)：
• 138kD

• Background：
• This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding d

• Function：
• catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in ERBB2 are associated with familial glioma of brain [MIM:137800]; also called glioblastoma multiforme. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas.,disease:Defects in ERBB2 are associated with gastric cancer [MIM:137215]; also known as hereditary familial diffuse gastric cancer (HDGC).,disease:Defects in ERBB2 are associated with lung cancer [MIM:211980]; also called adenocarcinoma of lung.,disease:Defects in ERBB2 are associated with ovarian cancer [MIM:167000]. Ovarian cancer is the leading cause of death from gynecologic malignancy. It is characterized by advanced presentation with loco-regional dissemination in the peritoneal cavity and the rare incidence of viscera

• Subcellular Location：
• Membranous

• Expression：
• Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs